Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan Nishida T; Tsujii M; Tanimura H; Tsutsui S; Tsuji S; Takeda A; Inoue A; Fukui H; Yoshio T; Kishida O; Ogawa H; Oshita M; Kobayashi I; Zushi S; Ichiba M; Uenoyama N; Yasunaga Y; Ishihara R; Yura M; Komori M; Egawa S; Iijima H; Takehara TWorld J Gastroenterol 2014[Apr]; 20 (15): 4362-9AIM: To evaluate the efficacy and safety of esomeprazole-based triple therapy compared with lansoprazole therapy as first-line eradication therapy for patients with Helicobacter pylori (H. pylori) in usual post-marketing use in Japan, where the clarithromycin (CAM) resistance rate is 30%. METHODS: For this multicenter, randomized, open-label, non-inferiority trial, we recruited patients (>/= 20 years of age) with H. pylori infection from 20 hospitals in Japan. We randomly allocated patients to esomeprazole therapy (esomeprazole 20 mg, CAM 400 mg, amoxicillin (AC) 750 mg for the first 7 d, with all drugs given twice daily) or lansoprazole therapy (lansoprazole 30 mg, CAM 400 mg, AC 750 mg for the first 7 d, with all drugs given twice daily) using a minimization method with age, sex, and institution as adjustment factors. Our primary outcome was the eradication rate by intention-to-treat (ITT) and per-protocol (PP) analyses. H. pylori eradication was confirmed by a urea breath test from 4 to 8 wk after cessation of therapy. RESULTS: ITT analysis revealed the eradication rates of 69.4% (95%CI: 61.2%-76.6%) for esomeprazole therapy and 73.9% (95%CI: 65.9%-80.6%) for lansoprazole therapy (P = 0.4982). PP analysis showed eradication rate of 76.9% (95%CI: 68.6%-83.5%) for esomeprazole therapy and 79.8% (95%CI: 71.9%-86.0%) for lansoprazole therapy (P = 0.6423). There were no differences in adverse effects between the two therapies. CONCLUSION: Esomeprazole showed non-inferiority and safety in a 7 day-triple therapy for eradication of H. pylori compared with lansoprazole.|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Anti-Ulcer Agents/administration & dosage[MESH]|Clarithromycin/pharmacology[MESH]|Drug Administration Schedule[MESH]|Drug Resistance, Bacterial[MESH]|Drug Therapy, Combination/*methods[MESH]|Esomeprazole/*administration & dosage[MESH]|Female[MESH]|Helicobacter Infections/*drug therapy[MESH]|Humans[MESH]|Japan[MESH]|Lansoprazole/*administration & dosage[MESH]|Male[MESH]|Middle Aged[MESH]|Prospective Studies[MESH]|Time Factors[MESH]|Young Adult[MESH] |
